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ABSTRACT
The chemokine CXCL12/stromal cell-derived factor-1 is important for leukocyte 
migration to lymphoid organs and inflamed tissues and stimulates tumor development. 
In vitro, CXCL12 activity through CXCR4 is abolished by proteolytic processing. 
However, limited information is available on in vivo effects of posttranslationally 
modified CXCL12. Natural CXCL12 was purified from the coculture supernatant of 
stromal cells stimulated with leukocytes and inflammatory agents. In this conditioned 
medium, CXCL12 with a nitration on Tyr7, designated [3-NT7]CXCL12, was discovered 
via Edman degradation. CXCL12 and [3-NT7]CXCL12 were chemically synthesized to 
evaluate the biological effects of this modification. [3-NT7]CXCL12 recruited β-arrestin 
2 and phosphorylated the Akt kinase similar to CXCL12 in receptor-transfected 
cells. Also the affinity of CXCL12 and [3-NT7]CXCL12 for glycosaminoglycans, the 
G protein-coupled chemokine receptor CXCR4 and the atypical chemokine receptor 
ACKR3 were comparable. However, [3-NT7]CXCL12 showed a reduced ability to 
enhance intracellular calcium concentrations, to generate inositol triphosphate, to 
phosphorylate ERK1/2 and to induce monocyte and lymphocyte chemotaxis in vitro. 
Moreover, nitrated CXCL12 failed to induce in vivo extravasation of lymphocytes to 
the joint. In summary, nitration on Tyr7 under inflammatory conditions is a novel 
natural posttranslational regulatory mechanism of CXCL12 which may downregulate 
the CXCR4-mediated inflammatory and tumor-promoting activities of CXCL12.
INTRODUCTION
The chemokine CXCL12 is a member of the CXC 
subgroup of chemotactic cytokines, which was previously 
purified from cell supernatant of the murine bone marrow 
stromal cell line MS-5 (hence its functional name stromal 
cell-derived factor-1/SDF-1) [1]. In addition to peripheral 
blood mononuclear cells (PBMCs), CXCL12 attracts 
neutrophils and CD34+ progenitor cells [2–5]. Recently, 
neutrophil-derived CXCL12-containing vesicles have 
been reported to be crucial for subsequent T cell migration 
to influenza-infected lungs [6]. CXCL12 also proved to 
be a co-stimulator for T cells [7]. Furthermore, CXCL12 
promotes the adhesion of lymphocytes to activated 
endothelial cells and the subsequent transendothelial 
migration of these leukocytes [8–11]. CXCL12 fulfills 
this function in both an inflammatory context and 
during homeostatic trafficking of lymphocytes [12, 13]. 
CXCL12 controls circulating neutrophil levels and aids 
in the rapid release of neutrophils from the bone marrow 
during inflammation [14]. CXCL12 has important 
homeostatic functions in B cell lymphopoiesis and is 
                   Research Paper
Oncotarget62440www.impactjournals.com/oncotarget
responsible for the homing of hematopoietic stem and 
progenitor cells to the bone marrow [15–20]. In contrast 
to other chemokines, CXCL12 is vital for embryogenesis, 
since CXCL12 knock-out mice are non-viable animals 
which die in utero or shortly after birth [16, 21]. This 
chemokine is responsible for the trafficking of endothelial 
progenitors to peripheral tissues to assist in angiogenesis, 
wound healing and tissue repair [22–24]. By using its 
angiogenic and migration-inducing properties, different 
types of cancer cells exploit the CXCL12/CXCR4 axis 
to promote tumoral angiogenesis, growth and metastasis 
[25–31]. Furthermore, CXCL12 plays a role in several 
autoimmune diseases like rheumatoid arthritis (RA) and 
multiple sclerosis (MS) [32–34].
CXCL12 binds the HIV co-receptor LESTR/
fusin and acts as a natural competitor for HIV-1 entry 
in T cells [35]. This receptor, now known as CXCR4, 
is the G protein-coupled receptor (GPCR) for CXCL12. 
CXCR4 activation results in intracellular release of 
Ca2+ and subsequent cellular responses like chemotaxis 
[29]. Moreover, CXCR7 was identified as a seven 
transmembrane-spanning receptor for both CXCL11 and 
CXCL12 [36, 37]. Since this receptor does not signal 
through G proteins but can activate β-arrestin-dependent 
signaling pathways, it was recently renamed atypical 
chemokine receptor 3 (ACKR3) [38, 39]. ACKR3 has 
a scavenging function, removing CXCL12 from the 
environment [40]. In addition to seven transmembrane-
spanning receptors, CXCL12 also interacts with 
glycosaminoglycans (GAGs) such as heparin and heparan 
sulfate [41].
Chemokines are regulated at multiple levels to 
control inflammation and homeostasis. Inflammatory 
chemokine expression can be upregulated by local 
transcription and stabilization of unstable chemokine 
mRNA following inflammatory stimuli [42]. They can 
also be stored in Weibel-Palade bodies or other secretory 
storage granules in endothelial cells, ready to be released 
upon an inflammatory stimulus [43]. Another regulation 
mechanism of chemokines, in particular CXCL12, 
occurs through alternative splicing at the translational 
level. CXCL12 is known to have six human splice 
variants (CXCL12 α to φ) with different forms being 
expressed in different tissues [44–46]. Furthermore, 
regulation of chemokine activity has also been reported 
to occur via posttranslational modification [47, 48]. These 
alterations include degradation, truncation at the N- or 
C-terminus and citrullination [47, 48]. The non-degrading 
modifications can either inactivate, reduce or enhance 
the chemokine function [49–52]. To become biologically 
active in vivo, CXCL5 even needs to be N-terminally 
truncated [53]. Since CXCL12 is a homeostatic chemokine 
and is important in many inflammatory processes, 
posttranslational regulation is necessary to control the 
levels of active chemokine [54]. Carboxypeptidase N 
and M, present in the blood circulation and membrane-
bound to bone marrow cells respectively, remove the 
C-terminal lysine of CXCL12α, reducing its biological 
activity [55, 56]. Also N-terminal truncation reduces the 
biological activity of CXCL12 and occurs in blood by 
the activity of CD26 [dipeptidyl peptidase IV (DPPIV)], 
cathepsin G, different members of the MMP family and 
neutrophil elastase [54, 57–62]. Recently, N-terminally 
truncated variants of CXCL12 were purified from human 
plasma, confirming the in vivo processing of CXCL12 
by some of the enzymes listed above [63]. Also, in vitro 
citrullination of Arg8 reduces the biological function of 
CXCL12, whereas citrullination of Arg8, Arg12 and Arg20 
or citrullination of all five arginine residues completely 
abolishes CXCL12 activity on CXCR4 [64].
Since natural CXCL12 is highly produced by bone 
marrow stromal cells, our interest was to analyze how 
this chemokine would be secreted and posttranslationally 
modified under inflammatory conditions. For this reason 
a stromal cell line was cocultered with leukocytes and 
stimulated with inflammatory agents. In addition to 
previously reported truncated CXCL12 forms, we here 
report the identification and functional characterization 
in vitro and in vivo of a novel natural posttranslationally 
modified CXCL12 form with nitration on Tyr7.
RESULTS
Production and purification of nitrated CXCL12 
from conditioned media of stimulated bone 
marrow stromal cells
Bone marrow stromal cells were cocultered with 
primary leukocytes and stimulated with both the cytokine 
interferon-γ (IFN-γ) and the Toll-like receptor 3 ligand 
polyinosinic:polycytidylic acid (poly I:C). CXCL12 was 
purified from the conditioned media by heparin affinity 
chromatography and reversed phase (RP) chromatography 
(Figure 1). The first purification step was based on the ability 
of the proteins to bind negatively charged GAGs (Figure 
1A). The bulk amount of proteins either did not bind to the 
column or eluted early (at <0.5M) in the NaCl gradient, as 
evidenced by the high total protein concentrations in the first 
28 column fractions. As determined by a specific CXCL12 
ELISA, CXCL12 eluted later (>0.5M) in the gradient 
(fractions 29 to 36). The heparin affinity chromatography 
fractions containing the highest concentrations (>1000ng/
ml) of CXCL12 were pooled as input for the RP-HPLC 
purification with on-line UV monitoring (Figure 1B). As 
detected by a specific CXCL12 ELISA, a single peak of 
CXCL12 eluted at 30% acetonitrile. After analysis by SDS-
PAGE, which confirmed the presence of pure CXCL12 
protein in the fractions (data not shown), the sequence 
of the purified CXCL12 was determined using Edman 
degradation. Interestingly, N-terminal peptide sequencing 
showed, in addition to the well-studied CXCL12(3-68) 
[61, 62], the presence of nitro-tyrosine on position 7 of 
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CXCL12, referred to as [3-NT7]CXCL12. No unmodified 
tyrosine was detected by Edman degradation on CXCL12 
eluting in fractions 52, 60 and 68 covering the elution peak 
of natural CXCL12. However, the nitrated form of CXCL12 
was not produced by unstimulated stromal cells (without 
addition of leukocytes or inflammatory stimuli).
Production of synthetic nitrated CXCL12 
variants
To investigate the in vitro and in vivo biological 
effects of N-terminal nitration of CXCL12, we first 
attempted to chemically nitrate CXCL12 using 
Figure 1: Purification of CXCL12 from stromal cell conditioned medium. MS-5 cells were stimulated with IFN-γ and the 
double-stranded RNA poly I:C in the presence of neutrophils and PBMCs. 72h after stimulation, conditioned medium was collected and 
purified using two consecutive chromatographic steps. Panel A shows the results from the heparin-Sepharose affinity chromatography. 
Proteins were eluted using a two-step sodium chloride gradient (dashed line). Total protein content was determined for each fraction using 
a BCA assay (open triangles). Total CXCL12 concentrations were determined for each fraction by ELISA (open crosses). Panel B shows 
the purification of the selected heparin-Sepharose fractions (i.e. fraction 29 to 32) by C8 RP-HPLC. Proteins were eluted using a gradient 
of acetonitrile in 0.1% (v/v) TFA (dashed line) and detected by their UV absorption (λ = 214nm, full line). CXCL12 concentrations were 
determined by ELISA (open crosses). mAU = milliabsorption units.
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peroxynitrite according to a previously described 
procedure [65]. However, following this protocol, i.e. 
an incubation of chemokine with 1mM of peroxynitrite 
in 100µl of PBS with 0.1% (w/v) BSA for 15 minutes 
at 37°C, no intact nitrated chemokine was detected 
(data not shown). Indeed, as the chemical treatment of 
CXCL12 was performed during different incubation 
periods, we detected more advanced degradation of 
the chemokine as incubation times were longer. As 
such, no intact chemokine was detected by SDS-PAGE 
after an incubation period longer than 8 minutes (data 
not shown). Because incubation of CXCL12 with 
peroxynitrite resulted in rapid CXCL12 degradation, we 
prefered to produce the nitrated CXCL12 synthetically, 
incorporating a nitrotyrosine at position 7, as was 
detected by Edman degradation on natural CXCL12. 
Both intact human CXCL12 and [3-NT7]CXCL12 
were chemically synthesized by Fmoc solid phase 
peptide synthesis, folded and purified. The Mr of each 
produced chemokine was confirmed by ion trap mass 
spectrometry (Figure 2). Unmodified synthetic CXCL12 
and [3-NT7]CXCL12 had an experimental Mr of 7960.3 
and 8005.5, respectively (theoretical Mr is 7959.4 and 
8004.4, respectively). The differences in Mr of the two 
CXCL12 forms with their theoretical Mr are well within 
the accuracy of the used mass spectrometer.
Glycosaminoglycan and CXCR4 binding 
properties of [3-NT7]CXCL12 equal those of 
native CXCL12
It was tested whether the presence of a 
nitrotyrosine in the N-terminal region of CXCL12 
altered its capacity to bind GAGs. Figure 3 shows 
the dose response curves for binding of CXCL12 
to heparin, heparan sulfate and dermatan sulfate. 
The absorbance of the highest dose (i.e. 120nM) of 
native, unmodified CXCL12 was set to 100% for each 
experiment. CXCL12 and [3-NT7]CXCL12 binding 
to each GAG was calculated as the percentage of the 
signal from 120nM CXCL12 in each experiment. The 
figure shows dose response curves with similar slopes 
for both CXCL12 forms. Only at the highest dose of 
120nM a minor but significant reduction in binding 
to heparin could be detected for [3-NT7]CXCL12 
compared to CXCL12.
In addition to binding to GAGs, binding of the 
native and nitrated CXCL12 to the CXCL12 receptors 
CXCR4 and ACKR3 was also evaluated in CXCR4-
transfected and ACKR3-transfected CHO cells (Figure 
4A and 4B, respectively). The ability of CXCL12 and 
[3-NT7]CXCL12 to compete with 12.5nM of Alexa Fluor 
647 labeled CXCL12 (CXCL12AF647) was comparable 
for both receptors. In Figure 4C and 4D, this comparable 
binding to both receptors was shown as raw FACS data for 
a representative experiment.
CXCR4 internalization by [3-NT7]CXCL12 is 
moderately reduced compared to CXCL12
Receptor internalization was also investigated 
in addition to binding characteristics. In general, the 
N-terminal part of chemokines is important for receptor 
activation. Figure 5A shows the dose-dependent capacity 
of CXCL12 and [3-NT7]CXCL12 to induce CXCR4 
internalization in CXCR4-transfected CHO cells. At high 
or low concentrations both forms were equally potent. 
However, at moderate concentrations (12.5nM and 
30nM) intact CXCL12 was significantly better at inducing 
CXCR4 internalization compared to its nitrated form. 
Previous reports showed that CXCR4 internalization is 
mediated by β-arrestin 2 recruitment to the cell membrane 
[66]. Therefore, we also tested whether CXCL12 and 
[3-NT7]CXCL12 display a different potency to induce 
β-arrestin 2 recruitment to CXCR4 or ACKR3 (Figure 5B). 
In this assay, although there was a trend towards reduced 
β-arrestin 2 recruitment to CXCR4 with [3-NT7]CXCL12, 
we could not detect a significant difference between both 
forms. Also for ACKR3 we could not measure an altered 
β-arrestin 2 recruitment.
Analyses of signal transduction capacities of [3-
NT7]CXCL12 show a reduced calcium signaling 
potency compared to native CXCL12
In addition, we investigated different signaling 
pathways known to be activated by CXCL12. The increase 
in intracellular calcium concentration ([Ca2+]i) following 
stimulation of CHO-CXCR4 and THP-1 cells with 
CXCL12 and [3-NT7]CXCL12 was measured (Figure 6). 
A representative experiment with THP-1 cells is shown 
in Figure 6A. On THP-1 cells (Figure 6B), every applied 
dose of CXCL12 induced a significantly higher increase 
of [Ca2+]i compared to its nitrated counterpart. For CHO-
CXCR4 cells (Figure 6C), the response after stimulation 
of the cells with 1.25nM and 12.5nM of CXCL12 was 
significantly higher than the increase in [Ca2+]i after 
stimulation of the cells with the same concentration of 
[3-NT7]CXCL12.
The phosphorylation of the kinases Akt and 
ERK after stimulation of CHO-CXCR4 cells with 
different concentrations of both CXCL12 forms was 
also investigated (Figure 7A and 7B). CXCL12 and 
[3-NT7]CXCL12 were equally potent in inducing 
Akt phosphorylation, whereas a significantly higher 
ERK1/2 phosphorylation was detected when the cells 
were stimulated with 1.25nM of CXCL12 compared to 
stimulation with 1.25nM [3-NT7]CXCL12. Evaluation of 
the formation of IP
3
 (Figure 7C) showed a significantly 
higher IP
3
 accumulation in the cytoplasm after stimulation 
of CXCR4-transfected COS-7 cells with 10nM and 100nM 
CXCL12 when compared to the nitrated CXCL12 form 
at these concentrations. Also ERK1/2 phosphorylation 
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Figure 2: Mass spectrometric analysis of synthetic CXCL12 and [3-NT7]CXCL12. Chemically synthetized human CXCL12 
and [3-NT7]CXCL12 were deprotected, folded and subsequently purified using RP-HPLC. Fractions were selected based on purity and 
correct relative molecular mass (Mr). Shown are the averaged mass spectrum of the final pool of synthetic purified and folded CXCL12 
(panel A) and [3-NT7]CXCL12 (panel B) with the number of charges for the detected ions, ion intensities and corresponding mass to charge 
ratios (m/z) for the multiply charged ions. The inserts in panels A and B show the deconvoluted mass spectra with the Mr of the uncharged 
proteins calculated using the Bruker deconvolution software.
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in human peripheral blood monocytes in response to 
CXCL12 or [3-NT7]CXCL12 was compared and a 
significantly higher phosphorylation after stimulation with 
3.75nM and 12.5nM CXCL12 was detected.
Compared to native CXCL12, the chemotactic 
potency of [3-NT7]CXCL12 for monocytic THP-1 
cells as well as lymphocytes is reduced
A main activity of chemokines when added to 
the appropriate cells is the induction of a chemotactic 
response. Therefore, chemotaxis assays were performed 
using monocytic THP-1 cells and freshly isolated 
PBMCs as a source of lymphocytes. THP-1 cell 
chemotaxis assays showed that CXCL12 was able to 
induce significant monocyte chemotaxis as compared 
to buffer solution at all concentrations except 1.25nM 
(Figure 8A). Stimulation with 3.75nM or higher 
concentrations of [3-NT7]CXCL12 induced a significant 
chemotactic response. However, at 3.75nM and 12.5nM, 
native CXCL12 was significantly more potent at 
inducing chemotaxis when compared to its nitrated form 
(maximum chemotactic index of 6.5 ± 1 for CXCL12, 
compared to 3.2 ± 0.4 for [3-NT7]CXCL12).
Figure 3: Binding properties of CXCL12 and its nitrated form to heparin, heparan sulfate and dermatan sulfate. 
Binding of CXCL12 (●, filled circles) and [3-NT7]CXCL12 (□, open squares) to heparin, heparan sulfate and dermatan sulfate are shown. 
CXCL12 and [3-NT7]CXCL12 (ranging from 0.5 nM to 120 nM in a threefold serial dilution) were added to GAG-coated wells. The 
amount of bound chemokine was determined using biotinylated anti-human CXCL12 antibodies and is represented by the mean percentage 
(n=6; ± SEM) of the absorbance at 450nm measured with 120nM CXCL12. Statistical comparison between CXCL12 and [3-NT7]CXCL12 
was performed using the Mann-Whitney U test (* p < 0.05).
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Chemotaxis of freshly isolated lymphocytes through 
fibronectin-coated membranes after 4h of incubation in 
response to different concentrations of CXCL12 forms 
showed a similar bell-shaped dose response curve. Both 
forms were able to induce significant in vitro lymphocyte 
chemotaxis compared to buffer solution at any given dose 
above 1nM (Figure 8B). At 37.5nM and 125nM, native 
CXCL12 induced a significantly higher lymphocyte 
chemotactic response compared to nitrated CXCL12 
(maximum CI of 4.2 ± 0.6 for CXCL12, compared to 2.5 
± 0.4 for [3-NT7]CXCL12).
[3-NT7]CXCL12 has a strongly reduced potency 
to attract lymphocytes in vivo
Given the reduced potency of [3-NT7]CXCL12 to 
induce chemotaxis of monocytes and lymphocytes in vitro, 
the ability of [3-NT7]CXCL12 to induce extravasation 
of lymphocytes was investigated in vivo. We evaluated 
CXCL12-induced lymphocyte recruitment into the joint 
upon injection of the chemokine in the tibiofemoral 
articulation. This model has the advantage of a very 
low basal leukocyte count upon vehicle injection. All 
tested chemokine doses of CXCL12 or [3-NT7]CXCL12 
depicted in Figure 9A caused significant extravasation of 
lymphocytes as compared to vehicle injection. However, 
an injection of 125pmol of CXCL12 caused significantly 
higher lymphocyte extravasation when compared to an 
injection of the same dose of [3-NT7]CXCL12 (3.3 x 
103 lymphocytes vs. 0.16 x103 lymphocytes). Even an 
injection with 375pmol of nitrated CXCL12 only resulted 
in a few lymphocytes migrating into the joint (median 
amount of 0.3 x 103 cells). Additional experiments were 
performed in a different animalium using a wider range of 
concentrations of the CXCL12 forms (Figure 9B). Here, 
only 12.5pmol of [3-NT7]CXCL12 was not able to recruit 
a significant amount of lymphocytes compared to vehicle. 
At other doses, [3-NT7]CXCL12 induced a statistically 
significant but limited infiltration of lymphocytes in 
the joint. At doses of 37.5pmol, 125pmol and 375pmol 
CXCL12 was significantly better at recruiting lymphocytes 
compared to [3-NT7]CXCL12.
Figure 4: Binding properties of CXCL12 and [3-NT7]CXCL12 to CXCR4 and ACKR3. CXCL12 (●, filled circles) and 
[3-NT7]CXCL12 (□, open squares) were added (concentrations ranging from 3.75nM to 375nM) to CHO-CXCR4 cells (panel A) or CHO- 
ACKR3 cells (panel B), together with 12.5nM CXCL12AF647 while the cells were kept on ice during the one hour incubation period. The 
results shown are the mean percentages (±SEM) of fluorescence compared to the control where only CXCL12AF647 was added to the cells 
(n=8 for the CXCR4 experiments, n=4 for ACKR3). Statistical comparison between CXCL12 and [3-NT7]CXCL12 was performed using 
the Mann-Whitney U test. Panels C and D show FACS data from a representative experiment with CHO-CXCR4 and CHO-ACKR3, 
respectively. The remaining fluorescence of CXCL12AF647 after competition with 37.5nM CXCL12 (black line) or 37.5nM [3-NT7]CXCL12 
(red line) are represented by two almost completely overlaying curves. The histogram where only CXCL12AF647 was added to the cell (grey 
area) shows the maximal fluorescence signal. The unstained control is also shown (dotted line).
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DISCUSSION
Reactive nitrogen species, of which nitric oxide 
(NO) is characterized the best, are a key part of the 
immune system and can have both a beneficial or 
malignant role [67,68]. NO is a short-lived free radical 
that can freely diffuse across cell membranes to fulfill 
its functions [67]. The production of NO is based on the 
balance between three enzymes that use L-arginine as a 
substrate, i.e. nitric oxide synthase (NOS) and arginases 
Figure 5: CXCR4 internalization and β-arrestin 2 recruitment through CXCR4 and ACKR3 in response to CXCL12 
and [3-NT7]CXCL12 stimulation. CXCL12 and its nitrated counterpart were compared for their ability to induce CXCR4 internalization 
(panel A) and β-arrestin 2 recruitment (panel B) through activation of CXCR4 or ACKR3. A. Using specific anti-CXCR4 antibodies, 
remaining receptor expression on CHO-CXCR4 cells was tested after one hour incubation at 37°C with CXCL12 (●, filled circles) or 
[3-NT7]CXCL12 (□, open squares). Both forms were added at concentrations ranging from 3.75 to 375nM. For each experiment, the 
fluorescence measured after stimulation with buffer only was set to 100%. Statistical analysis (n=4; ± SEM) was performed using the Mann-
Whitney U test (* p < 0.05). B. The recruitment of β-arrestin 2 in function of the ligand concentration (0.01nM to 1µM) was compared for 
CXCL12 (●, filled circles) and [3-NT7]CXCL12 (□, open squares) in CXCR4-transfected C2C12 cells (n ≥ 4) or ACKR3-transfected U2OS 
cells (n=3). The data shown are a mean percentage (± SEM) of the maximal β-arrestin 2 recruitment with unmodified CXCL12. Statistical 
differences between the two CXCL12 forms were analyzed using the Mann-Whitney U test.
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1 and 2. The arginases take part in the urea cycle where 
the end products are ornithine and urea, whereas NOS 
produces nitric oxide and superoxide anion [68]. The NOS 
family comprises three mostly constitutive NOS enzymes: 
neuronal (nNOS), endothelial (eNOS) and mitochondrial 
(mtNOS). In addition, a fourth member, inducible NOS 
(iNOS), is controlled by different cytokines and microbial 
triggers that either increase or decrease its expression, 
depending on the use of different signaling pathways [67]. 
Important NO producing cells are macrophages, assisting 
in pathogen removal, anti-tumor activity and tissue 
necrosis [69–71]. However, also immunosuppressive 
effects and the up- and downregulation of several 
cytokines, chemokines and growth factors have been 
described, adding to the complexity of NO in the immune 
system [67]. Also neutrophils and eosinophils produce 
NO in their anti-microbial and anti-tumoral function 
[72, 73]. Under sustained inflammation, reactive oxygen 
species (ROS) like superoxide anion reach high enough 
concentrations to either directly oxidize molecules or react 
rapidly with the produced NO to form the highly reactive 
peroxynitrite (ONOO-) that can nitrate tyrosine residues 
[74]. The presence of nitro-tyrosine is a commonly 
used marker of inflammation, since it is the result of the 
presence of both ROS and RNS in the microenvironment 
[74–77].
Many proteins can be subjected to tyrosine nitration. 
The effects of this posttranslational modification are 
diverse and may result in a decrease or loss of function, 
no alteration in activity or an increase of protein activity 
[68, 75, 77]. For chemokines, only the in vitro nitration 
of CCL2, CCL5 and CXCL12 by peroxynitrite have 
been described [78]. Chemical nitration of CCL5 
caused a significant reduction in chemotactic activity for 
eosinophils [79]. However, the reported data on CCL2 are 
less conclusive. One report shows that the treatment of 
CCL2 with peroxynitrite resulted in an impaired capacity 
to attract antigen-specific CD8+ T cells into the tumor 
tissue in mice, whereas CD14+ monocyte chemotaxis 
remained unaltered [65]. Sato et al., however, observed 
a reduced monocyte chemotactic activity after CCL2 
nitration [80]. Also CXCL12 was reported to be nitrated 
Figure 6: Calcium mobilization following CXCR4 activation with CXCL12 and [3-NT7]CXCL12. A. Real-time changes 
of intracellular calcium levels (Δ[Ca2+]i) are shown in function of time. After 60 seconds, indicated by the arrows, 3.75nM or 37.5nM of 
CXCL12 or [3-NT7]CXCL12 are added to CHO-CXCR4 cells. The summarizing figures of these calcium mobilization experiments are 
shown in panel B and C. B, C. The increase of free intracellular calcium ions after stimulation of THP-1 cells (panel B; n= 6; ± SEM) 
or CHO-CXCR4 cells (panel C; n=7; ± SEM) with CXCL12 (●, filled circles) and [3-NT7]CXCL12 (□, open squares) was monitored 
(concentrations ranging from 0.375nM to 37.5nM).
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chemically, which resulted in a loss of CD8+ T cell 
attraction [65]. However, in our hands the incubation 
of CXCL12 with peroxynitrite under the published 
conditions resulted in destruction of the protein. As 
discussed before, CXCL12 fulfills several functions 
in inflammation, and is often linked with enhanced 
inflammation. However, CXCL12 also functions as a 
protective chemokine in other conditions. In experimental 
autoimmune encephalitis (EAE), for example, CXCL12 
has been reported to have a protective role, attracting and 
redirecting the polarization of T helper cells to regulatory, 
IL-10-producing T cells [81]. As mentioned before, in 
an inflammatory environment often ROS and RNS are 
coproduced. Recently, it was reported that NO production 
in the inflamed central nervous system (CNS) inhibits 
the expression of CXCL12, preventing it to fulfill its 
protective function [82]. However, it is not known how 
CXCL12 is posttranslationally modified in an inflamed 
environment.
In our study, MS-5 bone marrow stromal cells were 
cocultured with neutrophils and PBMCs with the addition 
of the inflammatory stimuli IFN-γ and poly I:C. After 
purification of the conditioned medium, we identified for 
the first time naturally nitrated CXCL12: [3-NT7]CXCL12. 
These data confirm that CXCL12 can be subjected to 
tyrosine nitration and, moreover, that this modification can 
occur in a cell environment without CXCL12 degradation.
Using synthetic CXCL12 forms, the biological 
effect of CXCL12 nitration was verified in several 
assays. Binding to GAGs is indispensable for CXCL12 
and chemokine activity in general, as it is important 
for the formation of a chemokine gradient, promotes 
oligomerization and protects the chemokine from CD26-
mediated cleavage in blood and tissues [41, 83, 84]. The 
GAG binding experiments did not show a significant 
difference between CXCL12 and [3-NT7]CXCL12 for 
heparin, heparan sulfate and dermatan sulfate. Previous 
reports stated that the BBXB domain, where B stands for 
a basic amino acid and X for any other non-basic amino 
acid, is a key component in chemokine-GAG interaction 
[85]. As the tyrosine at position 7 is not located in the 
vicinity of these domains, a difference in GAG binding 
Figure 7: ERK, Akt and IP
3
 signal transduction pathways activated by CXCL12 and [3-NT7]CXCL12. The accumulation 
of second messengers after stimulation of different cell types with CXCL12 (●, filled circles) and [3-NT7]CXCL12 (□, open squares) is 
shown. A, B. The average accumulation (n=8; mean ± SEM) of phosphorylated Akt and ERK1/2 after a two minute stimulation of CHO-
CXCR4 cells with the CXCL12 forms (concentrations ranging from 3.75pM to 1.25nM) was calculated as a percentage compared to vehicle 
stimulated cells. C. IP
3
 generation (n=6; mean ± SEM) after stimulation of CXCR4-transfected COS-7 cells with both CXCL12 forms at 
concentrations ranging from 1pM to 100nM was measured. D. Fresh monocytes were stimulated with the CXCL12 forms (concentrations 
ranging from 1.25nM to 37.5nM). The average accumulation (n=9; mean ± SEM) of phosphorylated ERK1/2 after a two minute stimulation 
was calculated as a percentage compared to vehicle stimulated cells. All statistical analyses for differences between both CXCL12 forms 
were performed using the Mann-Whitney U test (* p < 0.05, ** p < 0.01, *** p<0.001).
Oncotarget62449www.impactjournals.com/oncotarget
due to its modification is unlikely. Also, the binding to 
both CXCR4 and ACKR3 was unaltered. Internalization 
and activation of CXCR4, considering β-arrestin 2, Akt 
and ERK1/2, were not or only moderately altered in the 
used cell lines. Also IP
3
 signaling was moderately but 
significantly reduced. However, ERK 1/2 phosphorylation 
was significantly reduced in fresh monocytes. Also 
β-arrestin 2 recruitment following ACKR3 activation was 
not affected by tyrosine nitration. This is in agreement 
with the fact that Tyr7 predominantly has a structural role 
and is not a key factor for receptor binding and activation, 
as was reported by Crump et al. [86].
Clear effects of Tyr7 nitration were seen in calcium 
mobilization assays. CXCL12 was confirmed to be able to 
induce the mobilization of calcium as a second messenger 
[87]. Nitration of the N-terminal tyrosine caused a 
Figure 8: In vitro chemotaxis of monocytes and lymphocytes towards CXCL12 and [3-NT7]CXCL12. Migration of 
monocytic THP-1 cells (panel A; n=7) and freshly isolated PBMCs (panel B; n=9) was compared towards CXCL12 (●, filled circles) 
and [3-NT7]CXCL12 (□, open squares) and is represented by chemotactic indices (mean ± SEM). Statistical differences between the two 
CXCL12 forms were determined using the Mann-Whitney U test (* p < 0.05, ** p < 0.01).
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significant reduction in the ability of CXCL12 to induce 
calcium fluxes in the cytoplasm. The clear effects of 
nitration on signal transduction through ERK1/2, IP
3
 and 
especially calcium following CXCR4 activation contrast 
with the absence of effect of nitration on the β-arrestin 
2 recruitment and might indicate a bias towards specific 
signaling pathways through CXCR4.
Signal transduction following the binding of 
a chemokine to its receptor leads in most cases to a 
chemotactic response of the target cell [41, 88]. In this 
study, we show that N-terminal tyrosine nitration of 
CXCL12 reduces its potency to attract lymphocytes in 
vitro. In addition, we also show significant reduction in 
chemotactic activity on monocytic THP-1 cells. This 
reduced migratory response of lymphocytes was further 
highlighted by the strong effect of nitration of CXCL12 
in vivo, where [3-NT7]CXCL12 was barely able to attract 
lymphocytes to the tibiofemural articulation. The stronger 
effect in vivo than in vitro could be the consequence of 
multiple factors that were affected by CXCL12 nitration.
In conclusion, we were the first to demonstrate that 
CXCL12 can be N-terminally nitrated in an inflamed 
environment. This posttranslational nitration did not 
have strong consequences on binding to GAGs and 
CXCR4 or ACKR3 in vitro. Although not influencing 
Akt signaling, we observed a significant reduction in the 
second messengers ERK, IP
3
 and calcium, which resulted 
in a reduced lymphocyte and monocytic THP-1 cell 
chemotaxis and was confirmed for lymphocytes in an in 
vivo setting. As such, nitration of CXCL12 may down-
regulate the function of CXCL12 in a pathological context.
MATERIALS AND METHODS
Cells
The murine bone marrow stromal cell line MS-5 
[89] was obtained from Prof. Y. Beguin (University of 
Liège, Liège, Belgium) [90] and cultured in Iscove’s 
Modified Dulbecco’s Medium (IMDM; Gibco, Auckland, 
New Zealand), enriched with 10% (v/v) fetal bovine serum 
(FBS; HyClone, Cramlington, UK), 5µg/ml gentamycin 
(Sigma-Aldrich, St. Louis, MO) and 3% (w/v) sodium 
bicarbonate (Gibco). Once confluent monolayers were 
obtained, 3% (v/v) FBS and 3% (w/v) sodium bicarbonate 
enriched IMDM was used.
The chinese hamster ovary (CHO) cell line 
transfected with CXCR4 was provided by Prof. Dr. 
M. Parmentier from the Institute of Interdisciplinary 
Research in Human and Molecular Biology (IRIBHM) 
at the Université Libre de Bruxelles, Brussels, 
Belgium. CHO cells were cultivated in Ham’s F-12 
growth medium (Lonza, Basel, Switzerland) including 
10% (v/v) FBS, 400µg/ml G418 (Gibco) and 250µg/
ml zeocin (Invitrogen, Carlsbad, CA). Human 
monocytic THP-1 cells (American Type Culture 
Collection, Manassas, VA) were cultured in Roswell 
Park Memorial Institute medium 1640 with glutamine 
supplement (RPMI 1640 - GlutaMAX; Gibco) which 
was further enriched with 10% (v/v) FBS and 3% (w/v) 
sodium bicarbonate. Both THP-1 and CHO cells were 
subcultivated two days prior to the signaling or cell 
migration assays.
Figure 9: In vivo recruitment of lymphocytes into the joint towards CXCL12 and [3-NT7]CXCL12. Vehicle, CXCL12 
or [3-NT7]CXCL12 were injected in a final volume of 10µl into the tibiofemoral articulation of C57BL/6 mice treated with sitagliptin. 3h 
post injection, the number of leukocytes migrated into the joint was determined and the % lymphocytes was counted differentially on May-
Grünwald-Giemsa stained cytospins. Each symbol represents an individual mouse (n ≥ 5). Horizontal lines indicate the median number of 
lymphocytes for each treatment group. The experiments were performed independently in Brazil A. and Belgium B. Statistical differences 
between groups of mice were determined using the Mann-Whitney U test (* p < 0.05, *** p < 0.001). All CXCL12 and [3-NT7]CXCL12 
doses except 12.5pmol [3-NT7]CXCL12 were significantly different from vehicle injection (p < 0.01).
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The mouse myoblast cell line C2C12 transfected 
with CXCR4 was obtained from DiscoveRx (Fremont, 
CA) and was cultured in Dulbecco’s Modified Eagle’s 
Medium 1885 (DMEM; Gibco), containing 20% (v/v) 
FBS and penicillin, streptomycin and L-glutamine. 
COS-7 cells transfected with CXCR4 were cultivated in 
DMEM 1885 enriched with 10% (v/v) FBS and penicillin, 
streptomycin and L-glutamine. U2OS cells were cultured 
in Minimal Essential Medium Alpha (MEM-alpha; 
Gibco) supplemented with 10% (v/v) FBS and penicillin, 
streptomycin, hygromycin and L-glutamine. The COS-
7 cells were cultured in an environment containing 10% 
CO2, all other cells were kept at the usual 5% CO2. 
Neutrophils, PBMCs and lymphocytes were isolated from 
buffy coats that were freshly provided by the Belgian Red 
Cross (Mechelen, Belgium) as previously described [91].
ELISA
The detection and quantification of CXCL12 was 
performed through enzyme-linked immunosorbent assays 
(ELISAs) using specific antibodies as described by Loos 
et al. [92]. Briefly, total CXCL12 concentrations were 
measured by coating a 96-well plate (Costar, Corning, 
NY) with 2µg/ml monoclonal anti-human/anti-mouse 
CXCL12 (Clone 79014; R&D Systems, Minneapolis, 
MN) and detecting the bound antigen with polyclonal 
biotinylated anti-human CXCL12 (Peprotech, Rocky 
Hill, NJ) at 250ng/ml. After incubation with streptavidine-
labeled horseradish peroxidase (R&D Systems), CXCL12 
concentrations were determined using the enzymatic 
activity of the horseradish peroxidase. This enzyme 
oxidizes the colorless 3,3’,5,5’-tetramethylbenzidine 
(TMB; Sigma-Aldrich) substrate into a blue product, using 
0.004% (v/v) H2O2 as oxidizing agent.
Chemokine production, purification and 
identification
MS-5 cells were stimulated with interferon-γ 
(Peprotech) and the double-stranded RNA poly I:C 
(Sigma Aldrich) at final concentrations of 20ng/ml and 
10µg/ml, respectively. Together with these inducers, also 
buffy coat-derived purified neutrophils and PBMCs were 
added at concentrations of, respectively, 3 x 105 cells/
ml and 4 x 105 cells/ml [91]. Conditioned medium was 
harvested after 72 hours and stored at -20 °C prior to 
purification.
A first purification step was performed using affinity 
chromatography with a heparin-Sepharose CL-6B column 
(1.6 x 40cm, 70ml volume; GE Healthcare, Uppsala, 
Sweden). The column was equilibrated with 50mM Tris-
HCl and 50mM NaCl, pH 7.4, at a flow rate of 10ml/hour 
before the sample was loaded. After washing the column 
with equilibration buffer the sample was eluted with 
a multi-step NaCl gradient ranging from 0.2 M to 2 M 
in 50mM Tris-HCl, pH 7.4, at a flow rate of 20ml/hour. 
Fractions of 5ml were collected and stored at -20°C.
Chemokine concentrations were assessed in these 
fractions by ELISA, whereas purity and total protein 
concentration were determined using sodium dodecyl 
sulphate polyacrylamide gel electrophoresis (SDS-
PAGE) on Tris/tricine gels under reducing conditions 
[93] and staining the protein with silver as described 
before [94]. Total protein concentrations were quantified 
by performing a bicinchoninic acid (BCA) assay on the 
collected fractions. Fractions containing chemokine 
were further purified by reversed-phase (RP)-HPLC 
using a C8 Aquapore RP-300 column (7µm, 220 x 
2.1mm; PerkinElmer, Waltham, MA). This column was 
equilibrated with 0.1% (v/v) trifluoroacetic acid (TFA; 
Biosolve, Valkenswaard, The Netherlands) in ultrapure 
water. After loading the heparin-Sepharose fractions on 
the RP-HPLC column, proteins were eluted by a 0% to 
80% acetonitrile gradient in 0.1% (v/v) TFA (Biosolve). 
Proteins were detected by UV (214nm) absorption 
and fractions of 0.4ml were collected and tested again 
using specific CXCL12 antibodies and SDS-PAGE with 
appropriate staining. N-terminal amino acid sequences 
of the proteins present in the fractions were determined 
by Edman degradation on a capillary protein sequencer 
(Procise 491 cLC, Applied Biosystems, Foster City, CA).
Chemical synthesis of CXCL12 and its nitrated 
variant
Intact CXCL12 and its nitrated variant, [3-NT7]
CXCL12, were chemically synthesized using fluorenyl 
methoxycarbonyl (Fmoc) chemistry on an Activo-P11 
solid phase peptide synthesizer (Activotec, Cambridge, 
UK) as previously described [95], with the inclusion of 
UV monitoring and the possibility of a second coupling 
step. Briefly, at least two piperidine treatments (2 and 5 
minutes) were used for every amino acid. As long as the 
UV signal of the removed Fmoc group remained higher 
than 25, additional piperidine treatments were performed 
with a maximum of 6 treatments (10, 15, 30 or 60 
minutes incubation periods for the 3rd up to 6th incubation 
with piperidine, respectively). Performing more than 2 
piperidine treatments triggers the double coupling module. 
In case of single coupling the added amino acid (10-fold 
excess compared to the amount of resin) was activated 
in 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium 
hexafluorophosphate/hydroxybenzotriazole (HBTU/HOBt) 
(0.5M/0.5M) and coupled for 20 minutes. When a double 
coupling step was needed due to the difficult removal of 
the Fmoc group of the previous amino acid, the amino 
acid used for the second coupling was activated with 
1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]
pyridinium 3-oxid hexafluorophosphate (HATU)/HOBt 
(0.5M/0.5M) and both the first and second coupling steps 
were elongated to one hour.
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[3-NT7]CXCL12 has a nitro-group at the ortho-
position of the benzene ring of the tyrosine residue at 
position 7. At this position, during the synthesis of [3-NT7]
CXCL12, an Fmoc-protected 3-nitrotyrosine residue (Iris 
Biotech, Marktredwitz, Germany) was incorporated in the 
amino acid sequence instead of a regular Fmoc-tyrosine.
The synthetic CXCL12 products (CXCL12 and [3-
NT7]CXCL12) were deprotected and cleaved from the 
resin by a 90 minute incubation at room temperature using 
a solution containing 0.75 g crystalline phenol, 0.5ml 
thioanisole, 0.25ml ethanedithiol and 0.5ml pure water in 
10ml TFA. Hereafter, the resin was removed by filtration 
and the deprotected peptides were precipitated and washed 
using diethyl ether. After lyophilization, chemokines were 
dissolved in ultrapure water and loaded on a RP-HPLC 
Source 5RPC column (4.6 x 150mm; GE Healthcare). 
Elution of the chemokines was obtained in an acetonitrile 
gradient as described before [95]. A fraction (0.7%) of 
the eluent was split to an ion trap mass spectrometer 
(Bruker Daltonics, Bremen, Germany) using a flow 
splitter (LC Packings, Amsterdam, The Netherlands). 
After deconvolution of the averaged spectra, fractions 
containing synthetic chemokine with the correct Mr were 
folded by incubating them overnight at room temperature 
in folding buffer containing 1M guanidium chloride, 
0.3mM reduced glutathione, 3mM oxidized glutathione 
and 3mM ethylenediaminetetraacetic acid (EDTA) in 
150mM Tris (pH 8.6). Folded chemokines were purified 
in the same manner as the natural chemokines, using a C8 
Aquapore RP-300 RP-HPLC column as described above, 
accompanied by on-line mass spectrometry to assure 
the correct molecular weight and purity of the synthetic 
proteins.
Glycosaminoglycan and receptor binding 
properties
The ability of [3-NT7]CXCL12 to bind to 
glycosaminoglycans was compared to native CXCL12 
using GAG binding plates (BD Biosciences, Franklin 
Lakes, New Jersey) coated overnight at room temperature 
with 25µg/ml heparin, heparan sulfate or dermatan 
sulfate (Iduron, Manchester, UK) in standard assay buffer 
(SAB; 100mM NaCl, 50mM sodium acetate, 0.2% (v/v) 
Tween-20; pH 7.2) as previously described [52]. Briefly, 
after thoroughly washing the plate with SAB buffer, the 
plates were blocked using SAB buffer enriched with 0.2% 
(w/v) gelatin for 1 hour at 37°C. After discarding the 
blocking buffer, serial dilutions of the synthetic CXCL12 
variants in blocking buffer were added to the heparin-
coated plates and incubated at 37°C for two hours. After 
a thorough washing step using SAB, bound chemokines 
were detected using the same procedure as described for 
the ELISA protocol. The data are shown as the percentage 
of maximum bound CXCL12, which was determined for 
each experiment.
The binding properties of the two different CXCL12 
variants to CXCR4 and ACKR3 were measured using 
CXCL12AF647 (Almac, Craigavon, Northern Ireland) in a 
previously described competition assay [64]. CHO cells, 
transfected with CXCR4 or ACKR3, were treated for 20 
seconds with EDTA-enriched trypsin (Lonza) to detach them 
from the culture flasks. Cells were resuspended in Ham’s 
F12 medium enriched with 10% (v/v) FBS and were allowed 
to restore their receptor expression after trypsinization for 
two hours at room temperature. After a washing step, 1.5 x 
106 cells/ml were incubated for 1 hour on ice with 12.5nM 
CXCL12AF647 and varying concentrations of unlabeled 
CXCL12 variants in a final volume of 200µl RPMI 1640 
enriched with 2% (v/v) FBS. After extensive washing in 
the same buffer, cells were fixed in RPMI 1640 with 2% 
(v/v) FBS and 0.4% (w/v) formaldehyde. The amount of 
fluorescence present on the cells was measured using flow 
cytometry (FACSCalibur flow cytometer, BD Biosciences).
Receptor internalization
Internalization of CXCR4 was measured using the 
CHO-CXCR4 cell line. Cells were removed from their 
cell culture flasks and allowed to restore basal receptor 
expression as described above [64]. Hereafter, the cells 
were washed twice using RPMI 1640 with 0.5% (v/v) 
human serum albumin (HSA, Belgian Red Cross). 
Finally, the cells were resuspended in this medium to a 
final concentration of 5 x 106 cells/ml. In a 96-well plate, 
100µl of this suspension was added to each well. Different 
concentrations of the tested CXCL12 forms were added 
to these cell cultures and allowed to incubate for one 
hour at 37°C. Hereafter, the cells were put on ice for the 
remainder of the experiment to prevent further changes 
in the receptor expression level. Also 200µl of ice-cold 
assay buffer (phosphate-buffered saline (PBS) with 2% 
(v/v) FBS) was added to the cells as a first washing step. 
A specific CXCR4/CD184 (Clone 12G5; BD Biosciences) 
antibody was diluted in ice-cold assay buffer to a working 
concentration of 12.5µg/ml and allowed to incubate for 
30 minutes. After two washing steps in ice-cold assay 
buffer, the cells were incubated for 30 minutes with 1.3µg/
ml of phycoerythrin-labeled goat anti-mouse IgG (BD 
Biosciences) in ice-cold assay buffer. After two washing 
steps in ice-cold assay buffer the cells were fixed using 
assay buffer with 0.4% (w/v) formaldehyde. The CXCR4 
expression on the cell surface was measured using flow 
cytometry (FACSCalibur flow cytometer). The data are 
presented as percentages of remaining receptor expression, 
where the maximal receptor expression was determined 
as the amount of fluorescence after stimulation with assay 
buffer only and incubation (37°C, 1 hour). Prevention of 
internalization and the absence of competition between 
the anti-CXCR4 antibody and CXCL12 was confirmed by 
keeping the cells on ice during the incubation using the 
highest dose of the CXCL12 forms (data not shown).
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Signal transduction assays
β-arrestin 2 recruitment to CXCR4 was performed 
using the PathHunter β-arrestin assay (DiscoveRx) 
as described previously [96], using C2C12 CXCR4 
transfectants. CXCR4 was C-terminally linked with a 
ProLink tag (PK; DiscoveRx) which combines with the 
second fragment of β-galactosidase to which β-arrestin 
2 is linked (enzyme acceptor (EA)-tagged β-arrestin 
2, DiscoveRx). Upon recruitment, both fragments 
(PK and EA) combine to generate the active enzyme. 
The recruitment of β-arrestin 2 to CXCR4 can thus be 
quantified measuring the produced luminescence one 
hour after addition of the appropriate substrates from the 
kit. β-arrestin 2 recruitment to ACKR3 was performed in 
a similar manner using U2OS that are stably transfected 
with EA-tagged β-arrestin 2 and transiently transfected 
with PK-tagged ACKR3.
Calcium mobilization was measured using both 
THP-1 and CXCR4-transfected CHO cells as previously 
described [52]. Briefly, the cells were resuspended in their 
respective culture medium with the addition of 2.5µM of 
the calcium binding fluorescent dye Fura-2 (Molecular 
Probes, Invitrogen) and 0.01% (w/v) pluronic F-127 
(Sigma-Aldrich) at a concentration of 107 cells/ml. To the 
CHO-CXCR4 cells also 125µM probenicid was added to 
block the release of Fura-2 from the cell. The cells were 
loaded with Fura-2 during 30 minutes at 37 °C. To account 
for the autofluorescence, 107 cells were not treated with 
Fura-2. After washing the cells, they were resuspended 
in calcium buffer to a final concentration of 106 cells/ml 
and kept at 4 °C from this point onwards. Calcium buffer 
was made using Hanks’ balanced salt solution (HBSS; 
Gibco) with 1mM Ca2+ and 10% (v/v) FBS, buffered with 
10mM HEPES/NaOH (Sigma-Aldrich) to pH 7.4 for THP-
1 cells and pH 7.0 for CHO-CXCR4 cells. Cells were 
shortly incubated at 37°C before measuring the calcium 
concentration after stimulation with various concentrations 
of the different CXCL12 forms. Fura-2 fluorescence was 
measured on a LS50B spectrofluorimeter (PerkinElmer) at 
510nm after alternating excitation at 340nm and 380nm.
Phosphorylation of Akt was tested on CHO-CXCR4 
cells and phosphorylation of ERK1/2 was tested using 
CHO-CXCR4 cells and fresh monocytes as described 
previously [97]. The cells were stimulated for 2 minutes 
with various concentrations of CXCL12 and [3-NT7]
CXCL12. The amount of phosphorylated ERK1/2 and 
Akt was determined using specific ELISA assays for 
Phospho-ERK1(T202/Y204)/ERK2(T185/Y187) and 
Phospho-Akt (S473) (duosets; R&D Systems). The ratio 
of phosphorylated ERK1/2 or Akt and the total amount 
of protein was calculated for each sample. The data are 
depicted as percentages compared to unstimulated control.
The inositol turnover assay was performed using 
CXCR4-transfected COS-7 cells which were transiently 
transfected using the previously described calcium 
phosphate transfection method [98]. Both cDNA of 
CXCR4 and the chimeric G protein GαΔ6qi4myr (7TM-
Pharma, Hørsholm, Denmark) were transfected to 
allow the cells to activate phospholipase C upon ligand 
stimulation. One day after transfection, cells were diluted 
to a concentration of 3.5 x 104 cells/ml in a poly-D-lysine-
coated 96-well plate. The cell medium was enriched with 
0.5µCi of Myo-[2-3H(N)]-inositol and the cells were 
incubated overnight at 37°C in 10% CO2. The radioactive 
medium was removed and cells were washed twice using 
HBSS. Hereafter, cells were incubated for 90 minutes at 
37°C with 100µl of 10mM LiCl in HBSS together with the 
CXCL12 forms in various concentrations. Subsequently, 
cells were lysed using 10mM formic acid with the plate 
put on ice for 30 minutes. Together with 35µl of cell 
extract, 80µl of 1:8 diluted YSi Poly-D-Lysine-coated 
beads (PerkinElmer) were added to a new 96-well plate 
and stirred vigorously. After centrifugation, the beads 
were allowed to react with the extract for at least 8 hours 
before luminescence was measured using the Packard Top 
Counter NXTTM (PerkinElmer).
Chemotaxis assays
Cell migration of THP-1 cells induced by the 
different CXCL12 variants was tested using a 96-well 
multiscreen plate (Millipore) as previously described 
[97]. Samples were diluted in RPMI 1640 with 0.1% 
(w/v) bovine serum albumin (BSA; Sigma-Aldrich). 
The THP-1 cells were diluted to a final concentration 
of 3.5 x 106 cells/ml in RPMI without phenol red and 
L-glutamine (Lonza) and incubated for 3 hours at 37°C. 
Hereafter, the filter plate with 5µm pores was removed 
and the migrated cells were quantified using the ATPlite 
kit (PerkinElmer). Chemotactic indices were calculated 
by dividing the luminescence intensity of the test sample 
by the luminescence intensity of the cells that migrated 
towards chemotaxis buffer alone.
Lymphocyte chemotaxis was performed in 
Boyden microchambers using unfractionated PBMCs 
that were allowed to migrate towards different 
concentrations of the CXCL12 forms under conditions 
which favor migration of the lymphocyte fraction of the 
PBMCs. These conditions include a 4 hour incubation 
period, a PBMC concentration of 10 x 106 cells/ml and 
the usage of a 5µm pore size, PVP-free fibronectin-
coated (25µg/ml) polycarbonate membrane [99]. 
Migrated cells were fixed and colored with Hemacolor 
solutions (Merck, Darmstadt, Germany) and counted 
microscopically using immersion oil and a 500-fold 
magnification. Chemotactic indices were calculated by 
dividing the amount of migrated cells by the amount 
of cells migrated towards buffer (HBSS enriched with 
0.5% (v/v) HSA) alone.
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In vivo cell migration assay
The effects of nitration of CXCL12 on the 
ability of CXCL12 forms to attract lymphocytes in 
vivo by extravasation from the blood circulation into 
the tibiofemoral articulation were examined by intra 
articular (i.a.) injection of the different CXCL12 forms 
in 8 weeks old wildtype C57BL/6 mice. Three days prior 
to the experiment, the water of the mice was changed 
to a 1.7mg/ml solution of the CD26 inhibitor sitagliptin 
[Merck Sharpe & Dohme (MSD), Whitehouse Station, 
NJ)] in water to partially block the activity of this 
enzyme for which CXCL12 is an efficiently cleaved and 
inactivated substrate [57]. Endotoxin levels in the injected 
samples were tested with the Limulus amoebocyte lysate 
test (Cambrex, East Rutherford, NJ) and were lower than 
0.125 pg LPS per µg chemokine. Different concentrations 
of the chemokine forms, diluted in a 0.9% (w/v) NaCl 
solution were injected i.a. as described previously [100], 
mice were placed under anaesthesia using 3.75% (w/v) 
ketamine, 0.25% (w/v) xylazine in PBS and injected 
i.a. with 10µl of the chemokine dilutions. After 3 hours 
of incubation, the mice were sacrificed and the articular 
cavity was washed using 3% (w/v) BSA in PBS. Total 
leukocytes were counted using a Neubauer chamber and 
Turk’s staining solution. Hereafter, the samples were 
counted differentially on May-Grünwald-Giemsa stained 
Cytospins (Shandon III). Experiments were performed 
in the animalia of the University of Minas Gerais and 
Leuven. All experiments using laboratory animals were 
reviewed and approved by the Animal Ethical Committee 
of the University of Minas Gerais and the Animal Ethical 
Committee of the University of Leuven.
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